WALTHAM, Mass., Oct. 2, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive cancers, announced today that it has priced its public offering of 2,750,000 shares of its common stock at a public offering price of $18.25 per share. In addition, Radius Health has granted the underwriters a 30-day option to purchase up to an additional 412,500 shares of common stock.
Jefferies LLC and Cowen and Company, LLC are acting as joint book-running managers and underwriters for the offering, and Cantor Fitzgerald & Co. is serving as co-manager.
The offering is being made pursuant to a shelf registration statement on Form S-3 filed with the Securities and Exchange Commission on September 2, 2014, which became effective on September 12, 2014. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of shares of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
A preliminary prospectus supplement describing the terms of the offering has been filed with the Securities and Exchange Commission and forms a part of the effective registration statement. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 547-6340 or by email at email@example.com, or Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (631) 274-2806 or by fax at (631) 254-7140.